drugset / Trial / NCT07570758
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.
Timeline
- Start
- 2026-05-28
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ERX1000 | Unknown | 2 mg | Oral |